Astria Therapeutics acquired by BioCryst; stockholders receive 0.59 shares + $8.55 cash per share

Pursuant to the Merger Agreement, at the Effective Time, Astria’s certificate of incorporation was amended and restated in its entirety in the form filed as Exhibit 3.1

and the bylaws of the Merger Sub became the bylaws of Astria in the form filed as Exhibit 3.2 to this Current Report on Form 8-K

Item 1.01. Entry Into a Material Definitive Agreement. On January 23, 2026 (the “ Closing Date ”), in connection with the Merger (as defined below) and immediately following the Effective Time (as defined below), Astria Therapeutics, Inc., a Delaware corporation (“ Astria ”), executed a joinder and thereby became a party to and guarantor under a Loan Agreement (the “ Loan Agreement ”) entered into on the Closing Date by BioCryst Pharmaceuticals, Inc., a Delaware corporation (“ BioCryst ”), as borrower, the guarantors from time to time party thereto, Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C., as the Blackstone representatives thereunder, the lenders from time to time party thereto and Wilmington Trust, National Association, as agent. The Loan Agreement provides for initial term loans in the principal amount of $400.0 million (the “ Term Loans ”), which were funded on the Closing Date. The maturity date of the Term Loans under the Loan Agreeme